Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment

2020 ◽  
Vol 33 (11) ◽  
pp. 1391-1397
Author(s):  
Daisuke Harada ◽  
Hiroko Kashiwagi ◽  
Kaoru Ueyama ◽  
Kyoko Oriyama ◽  
Yuki Hanioka ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Osteogenesis Imperfecta ◽  
Bone Strength ◽  
Bone Turnover Markers ◽  
Bone Fragility ◽  
Mineral Density ◽  
Before And After ◽  
Alendronate Treatment ◽  
Z Scores ◽  
Turnover Markers

AbstractObjectivesOsteogenesis imperfecta (OI) is a skeletal dysplasia characterized by recurrent fractures due to congenital bone fragility. The only bisphosphonate approved for OI in Japan is pamidronate (PAM). To investigate whether monthly intravenous alendronate (ALN) infusions can maintain bone strength in OI children following cyclical PAM treatment.MethodsA prospective and non-inferiority study was conducted. Eight school-age OI patients aged 8.5±2.0 years who were treated with cyclical PAM for 6.0±2.3 years were enrolled and switched to monthly intravenous ALN (0.030 mg/kg/month). Changes in L1-4 bone mineral density (BMD) Z-scores, fracture rates, and bone turnover markers for 12 months were analyzed.ResultsAverage BMD Z-scores were −3.0±1.9, −2.9±2.0, and −2.2±2.0 in 12 months before enrollment, at enrollment, and after 12 months of ALN treatment, respectively. BMD Z-scores increased significantly during treatment with both PAM and ALN (p=0.012), and the effect of ALN was not inferior to that of PAM (p=0.67). There was no change in fracture rates (p=0.86) and bone turnover markers during the 12 months before and after enrollment. Additionally, ALN showed no remarkable side effects.ConclusionsOur results suggest that monthly intravenous ALN can maintain bone strength after primary usage of cyclical PAM. We concluded that monthly intravenous ALN as a maintenance treatment following cyclical PAM administration can be an option for OI children.

Effect of suppression of puberty and cross-sex hormone therapy on bone turnover markers and BMAD in transgender adolescents

2016 ◽  
Vol 62 (5) ◽  
pp. 22-23
Author(s):  
Mariska Caroline Vlot ◽  
Daniel T. Klink ◽  
Martin Den Heijer ◽  
Marinus A. Blankenstein ◽  
Joost Rotteveel ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Hormone Therapy ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Sex Hormone ◽  
Added Value ◽  
Mineral Density ◽  
Bone Mineral Apparent Density ◽  
Z Scores ◽  
Turnover Markers

Background: Puberty is highly important for the accumulation of bone mass. Bone turnover and bone mineral density can be affected in transgender adolescents when puberty is suppressed by gonadotropin-releasing hormone analogues (GnRHa), followed by treatment with cross-sex hormone therapy (CSHT).Objective: To investigate the effect of GnRHa and CSHT on bone turnover markers (BTMs) and bone mineral apparent density (BMAD) in transgender adolescents.Methods: Thirty four female-to-males (FtMs) and 22 male-to-females (MtFs) were divided into a young and old pubertal group, based on the bone age of 14 years in the FtMs and 15 years in the MtFs. All patients received GnRHa triptorelin. CSHT was prescribed in incremental doses from the age of 16 years. FtMs received testosterone ester mixture and MtFs were treated with 17-β estradiol. BTMs P1NP, osteocalcin and ICTP and the BMD of lumbar spine (LS) and femoral neck (FN) were measured at three time points. Furthermore, BMAD and Z-scores were calculated.Results: P1NP and 1CTP decreased during GnRHa treatment, indicating decreased bone turnover. Osteocalcin showed an aberrant pattern. A low BMAD Z-score of both FN and LS was observed in the MtFs at start of GnRHa treatment. The decrease in bone turnover upon GnRHa treatment was accompanied by an unchanged BMAD of both FN and LS, however BMAD Z-scores of predominantly the LS decreased. Twenty-four months after CSHT the BTMs P1NP and ICTP were even more decreased. During CSHT BMAD Z-scores increased and returned towards normal, especially of the LS.Conclusion: Suppressing puberty by GnRHa leads to a decrease of BTMs in transgender adolescents. The increase of BMAD and BMAD Z-scores predominantly in the LS as a result of treatment with CSHT is accompanied by decreasing BTM concentrations after 24 months of CSHT. Therefore, the added value of evaluating BTMs seems to be limited and DEXA-scans remain important in follow-up of transgender adolescents. 

THE EFFECTS OF SQUARE DANCING ON BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS

2018 ◽  
Vol 18 (08) ◽  
pp. 1840027 ◽  
Author(s):  
JINZE QIN ◽  
XIAOXU RONG ◽  
GUOXING ZHU ◽  
YU JIANG
Keyword(s):  
Bone Turnover ◽  
Postmenopausal Osteoporosis ◽  
Research Group ◽  
Bone Turnover Markers ◽  
Bone Pain ◽  
Serum Levels ◽  
Control Group ◽  
Mineral Density ◽  
Before And After ◽  
Turnover Markers

Objective: To study the effects of square dance on bone mineral density (BMD) and bone turnover markers in patients with postmenopausal osteoporosis. Methods: Fifty postmenopausal women (aging 45–60) with osteoporosis were randomly assigned to a research group and a control group. The patients in the research group received 600[Formula: see text]mg of calcium combined with square dance (5 times a week, 30 to 60 minutes each time) for 6 months while those in the control group only received 600[Formula: see text]mg of calcium. BMD, changes in bone turnover markers and bone pain were assessed before and after the treatment. Results: (1) After the 6-month treatment, BMD of L[Formula: see text] and the femoral neck significantly increased in the research group ([Formula: see text]). No significant change was observed in BMD of the Ward’s region. BMD in the control group did not change significantly ([Formula: see text]). (2) No significant difference was found in serum levels of calcium, phosphorus and alkaline phosphatase between the two groups both before and after the treatment ([Formula: see text]). Serum levels of P1NP had a significant increase, while [Formula: see text]-CTX’s level did not change significantly. (3) The bone pain in both groups has been effectively relieved. The pain in the research group was relieved significantly compared to the control group. Conclusions: By improving the BMD and relieving the pain, square dancing can exert positive effects on women with postmenopausal osteoporosis. Square dancing may become a feasible strategy for osteoporosis prevention and treatment.

Bone mineral density and bone turnover markers in patients with thyroid cancer and L-T4 suppressive therapy after 25 years of follow-up

2014 ◽  
Author(s):  
Mingo Dominguez Maria Luisa de ◽  
Sonsoles Guadalix Iglesias ◽  
Maria Begona Lopez Alvarez ◽  
Guillermo Martinez Diaz-Guerra ◽  
Federico Hawkins Carranza
Keyword(s):  
Bone Mineral Density ◽  
Thyroid Cancer ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Suppressive Therapy ◽  
Mineral Density ◽  
Turnover Markers

Bone mineral density and bone turnover markers in women with connective tissue dysplasia

2019 ◽  
Vol 17 (4) ◽  
pp. 102-106
Author(s):  
M. Yu. Smetanin ◽  
◽  
S. Yu. Nurgalieva ◽  
N. Yu. Kononova ◽  
L. T. Pimenov ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Connective Tissue ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Connective Tissue Dysplasia ◽  
Turnover Markers

scholarly journals A Three-Year Longitudinal Study Comparing Bone Mass, Density, and Geometry Measured by DXA, pQCT, and Bone Turnover Markers in Children with PKU Taking L-Amino Acid or Glycomacropeptide Protein Substitutes

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2075
Author(s):  
Anne Daly ◽  
Wolfgang Högler ◽  
Nicola Crabtree ◽  
Nick Shaw ◽  
Sharon Evans ◽  
...  
Keyword(s):  
Amino Acid ◽  
Bone Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Blood Biochemistry ◽  
Reference Ranges ◽  
Mineral Density ◽  
Bone Mineral Apparent Density ◽  
Turnover Markers

In patients with phenylketonuria (PKU), treated by diet therapy only, evidence suggests that areal bone mineral density (BMDa) is within the normal clinical reference range but is below the population norm. Aims: To study longitudinal bone density, mass, and geometry over 36 months in children with PKU taking either amino acid (L-AA) or casein glycomacropeptide substitutes (CGMP-AA) as their main protein source. Methodology: A total of 48 subjects completed the study, 19 subjects in the L-AA group (median age 11.1, range 5–6 years) and 29 subjects in the CGMP-AA group (median age 8.3, range 5–16years). The CGMP-AA was further divided into two groups, CGMP100 (median age 9.2, range 5–16years) (n = 13), children taking CGMP-AA only and CGMP50 (median age 7.3, range 5–15years) (n = 16), children taking a combination of CGMP-AA and L-AA. Dual X-ray absorptiometry (DXA) was measured at enrolment and 36 months, peripheral quantitative computer tomography (pQCT) at 36 months only, and serum blood and urine bone turnover markers (BTM) and blood bone biochemistry at enrolment, 6, 12, and 36 months. Results: No statistically significant differences were found between the three groups for DXA outcome parameters, i.e., BMDa (L2–L4 BMDa g/cm2), bone mineral apparent density (L2–L4 BMAD g/cm3) and total body less head BMDa (TBLH g/cm2). All blood biochemistry markers were within the reference ranges, and BTM showed active bone turnover with a trend for BTM to decrease with increasing age. Conclusions: Bone density was clinically normal, although the median z scores were below the population mean. BTM showed active bone turnover and blood biochemistry was within the reference ranges. There appeared to be no advantage to bone density, mass, or geometry from taking a macropeptide-based protein substitute as compared with L-AAs.

Sign in / Sign up

Export Citation Format

Share Document